Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 24, 2026

Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV

View original at finance.yahoo.com
Better Health Care ETF: Fidelity's FHLC vs…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • XLV generated a growth of $1,284 from a $1,000 investment over five years on a total return basis, outperforming FHLC's $1,231 over the same period despite lower 1-year return

    60% confidence
  • FHLC has a trailing-12-month dividend of $1.01 per share, and its broader MSCI-based index captures small- and mid-cap companies that XLV skips

    60% confidence
  • XLV has paid $2.51 per share in distributions over the trailing 12 months, with a dividend yield of 1.7% versus FHLC's 1.4%

    60% confidence
  • XLV offers superior liquidity and a higher trailing-12-month dividend yield compared to FHLC, making it more suitable for income-seeking investors

    60% confidence
  • FHLC provides broader market-cap exposure including mid- and small-cap stocks, capturing companies that XLV skips by tracking only S&P 500 healthcare components

    60% confidence

Data points we hold from this source

AbbVie Inc. · portfolio weight in xlv7.09 percent
AbbVie Inc. · portfolio weight in fhlc6.06 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV — Source | Via News | ViaNews Market